Product Information
LYBALVI 20-10 MG TABLET is a brand product labeled by Alkermes, Inc., priced at $55.0457 per EA under NDC 65757065442. Its NADAC has been published 219 times since Apr 20, 2022.
Strength
20; 10 mg/1; mg/1
Manufacturer
Alkermes, Inc.NDC
65757065442
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
OLANZAPINE; SAMIDORPHAN L-MALATEApproval Type
New Drug (NDA)
FDA Application
NDA213378On Market Since
9/20/2021
Pharmacological Classes
Price Statistics
The NADAC for LYBALVI 20-10 MG TABLET has been published 219 times since Apr 20, 2022, and over the history we have for it it has risen 24.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $55.0457 per EA |
|---|---|
| All-time high | $55.1403 (Jun 10, 2026) |
| All-time low | $44.2732 (Apr 20, 2022) |
| 52-week high | $55.1403 |
| 52-week low | $52.2941 |
| Median price | $50.0750 |
| Average price | $49.7530 |
| Largest weekly change | +5.5% (Nov 23, 2022) |
| Weeks tracked | 219 |
| Tracking since | Apr 20, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the olanzapine and samidorphan L-malate market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of LYBALVI 20-10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LYBALVI 20-10 MG TABLET, manufactured by Alkermes, Inc., is $55.0457 per EA (NDC 65757065442), effective Jun 24, 2026.
How has the price of LYBALVI 20-10 MG TABLET changed over time?
Over the history we have for it, the NADAC for LYBALVI 20-10 MG TABLET has risen 24.3%. It has been tracked across 219 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for LYBALVI 20-10 MG TABLET?
Since Apr 20, 2022, the NADAC for LYBALVI 20-10 MG TABLET has ranged from a low of $44.2732 (Apr 20, 2022) to a high of $55.1403 (Jun 10, 2026), with a median of $50.0750 per EA.
Are there cheaper alternatives to LYBALVI 20-10 MG TABLET?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of LYBALVI 20-10 MG TABLET, so no direct lower-cost alternative is listed.
Who manufactures LYBALVI 20-10 MG TABLET?
LYBALVI 20-10 MG TABLET (NDC 65757065442) is labeled by Alkermes, Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification